Comparison of different discontinuation drug dose on Graves’ disease: A prospective clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ORC-13003429

Enrollment

Unknown

Registered

2013-08-08

Start date

2013-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves’ disease

Interventions

A:methimazole therapy with 5mgqd at drug withdrawal combined with euthyrox

B:methimazole therapy with 2.5mgqd at drug withdrawal combined with euthyrox

C:methimazole therapy with 2.5mgqod at drug withdrawal combined with euthyrox

Eligibility

Sex/Gender

All

Age

10 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Graves' disease; 2. All patients were first diagnosed and none of the patients had been treated for Graves' disease prior to inclusion.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients combined with thyroid tumor or thyroiditis; 3. Patients who is more suitable for radioiodine or surgery; 4. Serious hepatic impairment or agranulocytosis; 5. Patients after thyroid surgery or radioiodine therapy.

Design outcomes

Primary

Measure	Time frame
TSH;FT3;FT4;TT3;TT4;TMAb;TGAb;TPOAb;	—

Countries

China

Contacts

Public ContactBingyin Shi

shibingy@126.com+86 029-85323974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026